June 20, 2017 / 1:10 PM / 2 months ago

BRIEF-Ligand partner Melinta Therapeutics says FDA approves antibiotic Baxdela

June 20 (Reuters) - Ligand Pharmaceuticals Inc

* ligand’s partner melinta therapeutics announces u.s. Fda approval of baxdela™ (delafloxacin) for acute bacterial skin and skin structure infections (absssi)

* Ligand pharmaceuticals inc -as a result of approval, ligand has earned a $1.5 million milestone payment and will earn a 2.5% royalty on baxdela iv sales Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below